Duloxetine: Nursing Drug Guide, Hepatotoxicity & Serotonin Safety
Duloxetine is a delayed-release SNRI for depression, anxiety, neuropathic pain, and fibromyalgia. The bedside safety story is hepatotoxicity—fatal hepatic failure has been reported, and labeling says to discontinue for jaundice or clinically significant liver dysfunction—plus serotonin syndrome when MAOIs, linezolid, or serotonergic drugs stack, even with duloxetine alone. Swallow capsules whole; taper rather than stop abruptly.
Hepatic failure, sometimes fatal, has been reported with duloxetine—discontinue for jaundice or other clinically significant liver dysfunction and do not resume unless another cause is established; avoid use with substantial alcohol use or chronic liver disease. MAOIs, linezolid, and IV methylene blue are contraindicated within required washout windows. Serotonin syndrome can occur with other serotonergic drugs or when duloxetine is used alone—discontinue duloxetine and serotonergic agents if suspected. Gradually reduce dose when stopping; monitor blood pressure regularly. Swallow delayed-release capsules whole—do not crush, chew, or open.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm the delayed-release capsule is swallowed whole, screen for new serotonergic, MAOI, or anticoagulant orders, and review liver symptoms, alcohol use, and renal function. Hold and clarify if linezolid or IV methylene blue is ordered, if transaminases rise with jaundice, if GFR is below 30 mL/min without a documented exception, or if serotonin syndrome is suspected.
Most common brand names
Duloxetine is available as generic delayed-release capsules and as the brand Cymbalta. Verify both drug name and capsule strength (20 mg, 30 mg, or 60 mg)—look-alike confusion with venlafaxine and other antidepressants is a common source of inpatient errors.
Delayed-release capsules contain duloxetine hydrochloride. Do not substitute venlafaxine, fluoxetine, or another SNRI/SSRI without prescriber order—they are not milligram-equivalent.
Why we give it — Indications
Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain in adults per prescribing information. Pediatric use is approved for GAD (ages 7–17) and juvenile fibromyalgia (ages 13–17); pediatric MDD, DPNP, and chronic musculoskeletal pain are not established per labeling.
| Use | Detail |
|---|---|
| Major depressive disorder (adults) | Typical acute dosing 40–60 mg/day; maintenance often 60 mg/day; maximum studied 120 mg/day. Monitor suicidality, liver function, blood pressure, and taper when stopping. |
| Generalized anxiety disorder | Adults and pediatrics ≥7 years: usual 60 mg once daily; geriatric GAD may start 30 mg daily for 2 weeks before increasing. |
| Diabetic peripheral neuropathic pain | 60 mg once daily in adults; higher doses do not confer additional benefit and are less tolerated. Consider lower starting dose when renal impairment is present. |
| Fibromyalgia & chronic musculoskeletal pain | Often 30 mg daily for one week, then 60 mg once daily; pediatric fibromyalgia approved ages 13–17 per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The exact mechanism is unknown but is thought to involve potentiation of serotonin and norepinephrine in the central nervous system through reuptake inhibition. Duloxetine is formulated as a delayed-release capsule for once-daily oral administration; crushing, chewing, or opening the capsule can change drug release and exposure. Duloxetine is a moderate inhibitor of CYP2D6 and can raise concentrations of some co-medications metabolized by that pathway per labeling.
Dosing overview
Take once daily with or without food. Swallow capsules whole; do not crush, chew, or open. Dosing varies by indication—verify the MAR matches the labeled indication and renal/hepatic status.
MAOI switching: At least 14 days between stopping an MAOI intended to treat psychiatric disorders and starting duloxetine; at least 5 days after stopping duloxetine before starting an MAOI. Missed dose: Not specified in the reviewed prescribing information for a single missed-dose instruction. Do not double doses. Contact prescriber/pharmacy if multiple doses were missed—abrupt interruption increases discontinuation syndrome risk.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, allergies, and MAOI/linezolid/IV methylene blue status with required washout intervals (14 days after MAOI before start; 5 days after duloxetine stop before MAOI)
- Review liver disease, alcohol use, baseline ALT/AST if indicated, renal function (avoid GFR <30 mL/min), and blood pressure
- Confirm patient can swallow capsule whole; medication reconciliation for serotonergic and anticoagulant drugs after every new order
- Screen for suicidal ideation, bipolar history, narrow-angle glaucoma risk, seizure disorder, and hyponatremia risk (older adults, diuretics)
Contraindications
- Concomitant MAOIs intended to treat psychiatric disorders, or within 5 days of stopping duloxetine; do not start duloxetine within 14 days of stopping an MAOI
- Starting duloxetine in a patient treated with linezolid or intravenous methylene blue (serotonin syndrome risk)
- Uncontrolled narrow-angle glaucoma (pupillary dilation risk with antidepressants) per labeling warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAOIs / linezolid / IV methylene blue | Contraindicated — serotonin syndrome risk | Hold duloxetine; ensure 14-day washout before starting SNRI after MAOI; 5-day washout after stopping duloxetine before MAOI |
| Serotonergic drugs (e.g., tramadol, fentanyl, triptans, buspirone) | Increased serotonin syndrome risk (can occur with SNRI alone) | Reconcile medications each shift; hold and escalate if hyperthermia, agitation, clonus |
| Antiplatelets / anticoagulants (aspirin, NSAIDs, warfarin) | Increased bleeding risk with serotonin reuptake inhibition | Monitor for bruising, epistaxis, GI bleeding; trend INR when warfarin co-prescribed per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral delayed-release capsule once daily, with or without food.
- Swallow capsules whole—do not crush, chew, or open
- Give at the same time each day per MAR
- When discontinuing, reduce dose gradually whenever possible per prescriber/pharmacy taper plan
Opening or crushing the capsule destroys delayed-release properties and can increase peak exposure and adverse effects including hepatotoxicity risk. If the patient cannot swallow whole capsules, contact pharmacy for an alternative strategy—do not open capsules on the unit without pharmacy approval.
Expected therapeutic response
- Gradual improvement in depressive symptoms over weeks—not immediate
- Early therapy may include nausea, insomnia, or anxiety before mood benefit—distinguish expected side effects from worsening depression or suicidality
- Reassess continued need periodically; when stopping, taper over weeks to months in some patients per labeling
Red flags — Stop and act
Escalate urgently when hepatotoxicity, serotonergic toxicity, discontinuation crisis, or neuropsychiatric deterioration is suspected.
- Jaundice, dark urine, right upper abdominal pain, or transaminases >3× ULN with clinical liver dysfunction—discontinue per labeling
- Serotonin syndrome: agitation, hallucinations, tachycardia, labile BP, hyperthermia, tremor, rigidity, hyperreflexia, clonus, diarrhea—can occur with duloxetine alone or with serotonergic co-drugs
- Severe discontinuation symptoms after missed doses or rapid taper: electric-shock sensations, severe dizziness, irritability, confusion, suicidal thoughts
- Sustained blood pressure elevation, orthostatic hypotension with falls/syncope, or seizure
- Severe skin reaction: blisters, peeling rash, mucosal erosions—discontinue at first appearance per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, dry mouth, somnolence, constipation, decreased appetite, hyperhidrosis | Most common adult reactions (≥5% and at least twice placebo): nausea, dry mouth, somnolence, constipation, decreased appetite, hyperhidrosis per labeling | Supportive care; fall precautions with somnolence/dizziness; document if severe |
| Hepatotoxicity | Hepatic failure (sometimes fatal) reported; ALT >3× ULN in 1.25% of duloxetine-treated adults vs 0.45% placebo in trials | Discontinue for jaundice or clinically significant liver dysfunction; avoid chronic liver disease/substantial alcohol use |
| Elevated blood pressure / orthostatic hypotension | Monitor BP before and during therapy; orthostatic hypotension, falls, and syncope reported—especially after dose increases | Serial BP and orthostatic vitals; consider dose reduction or discontinuation if symptomatic |
| Serotonin syndrome | Potentially life-threatening; increased with serotonergic co-drugs or MAOIs; can occur with duloxetine alone | Stop duloxetine and serotonergic agents; supportive care; urgent escalation |
| Discontinuation syndrome | Dizziness, headache, nausea, paresthesia, irritability, insomnia, anxiety, hyperhidrosis, fatigue after abrupt or tapered stop | Taper when possible; do not abruptly restart high dose without prescriber plan |
| Hyponatremia / SIADH | Can occur; greater risk in older adults | Check sodium if confusion, headache, falls; hold and treat per protocol |
| Bleeding | Increased risk with aspirin, NSAIDs, and anticoagulants per labeling | Monitor bruising and GI bleeding; postpartum hemorrhage risk reported near delivery |
| Sexual dysfunction | May cause symptoms of sexual dysfunction per labeling | Nonjudgmental assessment; coordinate with prescriber if adherence affected |
On a small screen, swipe or scroll sideways to see the full table.
Frequency data above reflect CYMBALTA labeling unless noted as postmarketing.
Overdose, toxicity, and antidote
Fatal outcomes have been reported for acute duloxetine overdoses, including duloxetine-only ingestions up to 1000 mg (approximately 8.3 times maximum recommended dosage). Signs and symptoms include somnolence, coma, serotonin syndrome, seizures, syncope, tachycardia, hypotension, hypertension, and vomiting—often with mixed drugs.
Antidote
There is no specific antidote to duloxetine overdose per prescribing information. If serotonin syndrome ensues, specific treatment (such as cyproheptadine and/or temperature control) may be considered. Supportive care includes airway management, monitoring cardiac rhythm and vitals, and activated charcoal if appropriate and soon after ingestion.
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for overdose management recommendations.
Look-alike / sound-alike and error prevention
- Duloxetine vs venlafaxine — different agents and formulations; verify generic name on every administration
- Cymbalta vs other “C” drugs — confirm SNRI identity and capsule strength (20, 30, 60 mg)
- 20 mg vs 30 mg vs 60 mg — do not assume all capsules are 60 mg; read imprint and MAR
- Delayed-release capsule handling — never crush, chew, or open; pharmacy must be involved if swallowing is impaired
- SNRI/SSRI cross-dispense — sertraline and venlafaxine are not interchangeable milligram-for-milligram with duloxetine
- MAOI washout — 14-day gap after MAOI before duloxetine; 5 days after duloxetine before MAOI; document stop dates in MAR
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May be given with or without food per labeling. |
| Crush/open | Contraindicated per labeling—capsules must be swallowed whole. Contact pharmacy for dysphagia alternatives. |
| Onset | Antidepressant and pain benefit are not immediate; educate that improvement may take weeks while monitoring suicidality, liver symptoms, and BP. |
| Alcohol / liver | Avoid prescribing to patients with substantial alcohol use or chronic liver disease per labeling. |
| Commonly missed | New serotonergic analgesic or antibiotic orders, opening capsules for administration, and continuing 60 mg when GFR <30 mL/min. |
| Ask pharmacy when | Hepatic/renal contraindication unclear, swallowing difficulty, serotonergic stack, rising LFTs, or discontinuation symptoms without taper orders. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Age ≥65 years | Increased incidence of systolic orthostatic hypotension per labeling; greater hyponatremia risk; consider reduced renal clearance when dosing |
| Renal impairment | Avoid use when GFR <30 mL/min; consider lower starting dose in diabetic neuropathy when renal disease complicates diabetes |
| Hepatic impairment / alcohol | Avoid chronic liver disease or cirrhosis; do not use with substantial alcohol use; clinically evident hepatic impairment greatly increases exposure |
| Smoking | Bioavailability reduced by about one-third in smokers per labeling; dosage modification not recommended based on smoking alone |
| Seizure disorder | Seizures reported in pre-marketing studies; use cautiously in patients with seizure disorder per labeling |
| Untreated narrow-angle glaucoma | Avoid antidepressants including duloxetine in untreated anatomically narrow angles; pupillary dilation may trigger angle closure per labeling |
| Pregnancy | Third trimester use may increase risk of neonatal poor adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, irritability). Duloxetine use in the month before delivery may increase postpartum hemorrhage risk per labeling. Weigh untreated maternal illness vs drug risks; National Pregnancy Registry for Antidepressants available. |
| Lactation | Duloxetine is present in human milk; reports of infant sedation, poor feeding, and poor weight gain. Monitor breastfed infants for these signs per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mental status and suicidal ideation—especially first months and after dose changes (boxed warning for children, adolescents, and young adults)
- Blood pressure at baseline and periodically; orthostatic vitals when dizziness or falls occur
- Liver function if symptoms or risk factors (jaundice, abdominal pain, alcohol use); sodium in older adults; bleeding on anticoagulants
- Glucose/HbA1c in diabetic neuropathy patients per labeling
Document
- Dose, route, time, capsule strength, and confirmation capsule was swallowed whole (not opened)
- Suicide risk screening, liver symptom checks, serotonin syndrome assessment, discontinuation symptoms, and teaching provided
- BP trends, LFT/sodium results, taper plans, and prescriber/pharmacy notifications for holds or serotonergic interactions
Patient teaching
- Take exactly as prescribed at the same time daily; swallow the capsule whole—do not crush, chew, or open
- Do not stop abruptly—contact the clinician before stopping; gradual dose reduction is recommended when possible
- Report yellowing of skin or eyes, dark urine, abdominal pain, fever with muscle rigidity, severe agitation, or suicidal thoughts immediately
- Avoid starting MAOIs, St. John’s wort, or extra pain medicines without medical advice—serotonin syndrome risk
- Limit alcohol; report unusual bleeding or bruising, especially if taking blood thinners; pain or mood benefit may take weeks
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Patient on MAOI, linezolid, or IV methylene blue, or within required MAOI washout window (14 days after MAOI before start; 5 days after stop before MAOI)
- Jaundice or other clinically significant liver dysfunction; substantial alcohol use or chronic liver disease without prescriber exception
- Severe renal impairment (GFR <30 mL/min) without documented prescriber exception
- Suspected serotonin syndrome, seizure, severe hyponatremia, or severe skin reaction (blisters, peeling rash)
- Patient cannot swallow capsule whole and no pharmacy-approved alternative is available
- Multiple consecutive doses missed without prescriber restart/taper plan—high discontinuation syndrome risk
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Duloxetine safety on shift centers on liver injury surveillance, serotonergic interaction checks, and delayed-release capsule integrity—especially when new antibiotics, analgesics, or alcohol use appear on the chart.
1. Check-before-you-give protocol
- Right patient, drug, dose (verify indication-specific dose—often 60 mg), route, time, and intact delayed-release capsule
- Review MAR + home meds for MAOIs, linezolid, serotonergic analgesics, and anticoagulants at admission and after every new order
- Screen for jaundice, abdominal pain, alcohol use, and renal function before first inpatient dose
- Brief mood/suicide screen, BP check, and fall risk if dizziness or orthostasis present
2. High-alert and safety badge
Not an ISMP high-alert medication — still requires hepatotoxicity and serotonin safety checksAlthough not classified in the same tier as IV anticoagulants or concentrated electrolytes, duloxetine carries a boxed warning for suicidality in children, adolescents, and young adults, reports of fatal hepatic failure, and potentially life-threatening serotonin syndrome—treat liver monitoring, MAOI washout, and capsule handling as mandatory high-risk nursing steps.
3. Clinical workflow: hold and question rules
- Hold and notify prescriber/pharmacist if linezolid is ordered or LFTs rise with jaundice—do not administer next dose until clarified
- Stop and escalate if serotonin syndrome criteria met—discontinue duloxetine and serotonergic agents per labeling
- Coordinate gradual taper when discontinuing; never open or crush capsules on the unit without pharmacy approval
4. Critical teach-back questions
- “How should you take this capsule?” — swallow whole daily; do not crush, chew, or open; contact clinician before stopping
- “What symptoms require urgent care?” — yellow skin/eyes, severe abdominal pain, fever with muscle rigidity, severe agitation, or suicidal thoughts
5. Care coordination
Pharmacist: Renal/hepatic contraindication checks, serotonergic interaction review, capsule handling, and taper planning
Prescriber / mental health: Suicide risk management, liver monitoring, MAOI washout when switching antidepressants, and pain/psychiatry indication alignment
🧠 Quick mental checklist
- Can the patient swallow the delayed-release capsule whole—and is today’s dose correct for indication and renal/hepatic status?
- Any jaundice, abdominal pain, or rising LFTs since therapy started?
- Any new serotonergic drug (tramadol, triptan, linezolid) or MAOI exposure?
- Latest BP, sodium, and mood/suicide screen after dose changes?
- Is this duloxetine (Cymbalta)—not venlafaxine—and the correct 20/30/60 mg capsule?
Duloxetine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for duloxetine using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, ordered documentation steps, matrix urgency sorting, and MAOI washout cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around hepatotoxicity and serotonin syndrome prevention.
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Duloxetine 60 mg DR capsule PO daily — due 1200; last dose given yesterday (contents sprinkled on applesauce per prior shift note)
- Linezolid 600 mg IV q12h — first dose given 0800 today for cellulitis
- Tramadol 50 mg PO q6h PRN pain — 1 dose at 0730
- Aspirin 81 mg PO daily — given 0800
- ALT 142 U/L (was 38 U/L on admission); AST 118 U/L (was 42 U/L)
- Total bilirubin 2.1 mg/dL (was 0.8 mg/dL)
- Sodium 136 mmol/L; creatinine 0.9 mg/dL; estimated ClCr 82 mL/min
- Blood pressure 156/94 mmHg (was 128/76 at admission)
- 52-year-old with fibromyalgia and chronic low back pain; duloxetine 8 weeks
- Reports 4–5 alcoholic drinks nightly; no MAOI use documented
- Difficulty swallowing capsules—asked prior nurse to “open the pill”
- No history of linezolid before today
- 1010: Right upper quadrant discomfort; mild nausea; sclera appear slightly yellow to bedside nurse
- 1015: Restless, anxious; HR 98/min; temp 37.2 °C
- 1020: Reviewing MAR before 1200 duloxetine—notes new linezolid and tramadol
- 1025: Reflexes 2+ symmetric; no clonus; patient denies fever or rigidity
Answer key & rationale
Frequently asked questions
What should nurses check before giving duloxetine?
Confirm indication and dose (often 60 mg once daily for DPNP, fibromyalgia, and chronic musculoskeletal pain; MDD typically 40–60 mg/day). Screen for MAOI, linezolid, or IV methylene blue use and required washout intervals. Review liver history, alcohol use, renal function (avoid if GFR less than 30 mL/min), blood pressure, serotonergic and anticoagulant co-medications, and ability to swallow the delayed-release capsule whole without crushing or opening.
When should a nurse hold duloxetine?
Hold when MAOIs, linezolid, or IV methylene blue are present or within required washout windows; when serotonin syndrome is suspected; when jaundice or clinically significant liver dysfunction occurs; when severe renal impairment applies without prescriber exception; when the capsule cannot be swallowed whole; or when abrupt discontinuation symptoms emerge without a taper plan.
Is there a specific antidote for duloxetine overdose?
There is no specific antidote to duloxetine overdose per prescribing information. Management is supportive; if serotonin syndrome ensues, specific treatment such as cyproheptadine and temperature control may be considered. Contact local poison control or medical toxicology services per facility protocol.
Can duloxetine capsules be opened or crushed?
No. Prescribing information requires delayed-release capsules be swallowed whole and not crushed, chewed, or opened because altering the capsule can change drug release and exposure.
What labs and vitals should nurses monitor on duloxetine?
Monitor blood pressure at baseline and periodically; assess liver function if symptoms or risk factors for hepatotoxicity; check sodium in at-risk patients; track mood and suicidality especially during initiation and dose changes; and monitor for bleeding when antiplatelets or anticoagulants are co-prescribed.
References
-
U.S. FDA / DailyMed — CYMBALTA (duloxetine delayed-release capsules) prescribing information (Eli Lilly and Company)https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba
-
StatPearls — Duloxetine (NCBI Bookshelf)https://www.ncbi.nlm.nih.gov/books/NBK470587/
-
U.S. FDA — Drug Safety Communication: Suicidal thoughts and behavior with antidepressant drugshttps://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidal-thoughts-and-behavior-antidepressant-drugs
-
National Pregnancy Registry for Antidepressants — Massachusetts General Hospital Center for Women’s Mental Healthhttps://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants
-
DailyMed — CYMBALTA Medication Guide (patient-facing label companion)https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.